Target intelligence / Profile preview

Beta-transducin repeat-containing protein (BTRC)

Target
BTRC
Molecular classification
E3 ubiquitin ligase, F-box protein, SCF complex component, Enzyme
01

Overview

Beta-transducin repeat-containing protein (BTRC), also known as beta-TrCP1, is a critical F-box protein that serves as the substrate recognition subunit of the SCF (Skp1-Cullin1-F-box) E3 ubiquitin ligase complex [UniProt: P63151]. It plays a pivotal role in cellular homeostasis by mediating the phosphorylation-dependent ubiquitination and subsequent proteasomal degradation of key regulatory proteins, including beta-catenin, IkappaB, and CDC25A [PubMed: 15181464]. Through these interactions, BTRC modulates essential signaling pathways such as Wnt/beta-catenin and NF-kappaB, which govern cell proliferation, survival, and the immune response [NCBI Gene: 8945]. In the context of disease, BTRC is often dysregulated in various malignancies, including colorectal and pancreatic cancers, where it can function as either an oncogene or a tumor suppressor depending on the specific cellular context and the stability of its substrates [PubMed: 24513166]. Furthermore, BTRC is exploited by viruses like HIV-1, which uses its Vpu protein to hijack the ligase and degrade CD4, facilitating viral release [PubMed: 9843217]. Therapeutically, BTRC is being explored as a recruitment module for Proteolysis Targeting Chimeras (PROTACs) to induce the degradation of neo-substrates, although its broad range of natural targets poses challenges for achieving high specificity and minimizing systemic toxicity [PubMed: 32111836].

Other names
F-box/WD repeat-containing protein 1AFBXW1Abeta-TrCP1BTRCPFBXW1F-box and WD repeats protein beta-TrCP
02

Mechanism of action

Substrate recognition and recruitment for SCF-type E3 ubiquitin ligase-mediated polyubiquitination and subsequent 26S proteasomal degradation.

03

Biological functions

Protein ubiquitinationProteasomal degradationWnt signaling pathwayNF-kappaB signaling pathwayCell cycle regulationSignal transductionApoptosis regulation
04

Disease associations

CancerInflammationInfectionHIV-1 infectionAutoimmune disease
05

Safety considerations

Systemic toxicity due to pleiotropic effects on essential signaling pathwaysPotential for off-target protein degradation when used in PROTACsDisruption of homeostatic Wnt and NF-kappaB signalingRisk of promoting oncogenesis by stabilizing or degrading context-dependent substrates
06

Interacting drugs

PROTACs (as E3 ligase recruiter)

3 more in the full profile.

07

Biomarkers

beta-catenin protein levelsIkappaBalpha phosphorylation/degradation statusBTRC mRNA expressionCDC25A protein stability

Beyond the preview

Go deeper on Beta-transducin repeat-containing protein (BTRC).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beta-transducin repeat-containing protein (BTRC).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call